Hologic, Inc. [HOLX] stock is trading at $77.53, up 1.91%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The HOLX shares have gain 1.79% over the last week, with a monthly amount glided 3.93%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 2, April 2024, Hologic to Announce Financial Results for the Second Quarter of Fiscal 2024 on Thursday, May 2, 2024. In a post published today on Yahoo Finance, Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2024 on Thursday, May 2, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
From an analyst’s perspective:
Hologic, Inc. [NASDAQ: HOLX] stock has seen the most recent analyst activity on April 03, 2024, when Citigroup upgraded its rating to a Buy and also boosted its price target to $95 from $80. Previously, Needham upgraded its rating to Buy on July 14, 2023, and kept the price target unchanged to $95. On December 07, 2022, RBC Capital Mkts initiated with a Sector Perform rating and assigned a price target of $75 on the stock. Mizuho started tracking the stock assigning a Buy rating and suggested a price target of $75 on October 13, 2022. UBS initiated its recommendation with a Neutral and recommended $73 as its price target on July 20, 2022. BofA Securities downgraded its rating to Neutral for this stock on July 20, 2022, and downed its price target to $75. In a note dated July 18, 2022, BTIG Research downgraded an Neutral rating on this stock.
Hologic, Inc. [HOLX] stock has fluctuated between $64.02 and $87.88 over the past year. Currently, Wall Street analysts expect the stock to reach $81.2 within the next 12 months. Hologic, Inc. [NASDAQ: HOLX] shares were valued at $77.53 at the most recent close of the market. An investor can expect a potential return of 4.73% based on the average HOLX price forecast.
Analyzing the HOLX fundamentals
Hologic, Inc. [NASDAQ:HOLX] reported sales of 3.97B for the trailing twelve months, which represents a drop of -5.69%. Gross Profit Margin for this corporation currently stands at 0.62% with Operating Profit Margin at 0.19%, Pretax Profit Margin comes in at 0.19%, and Net Profit Margin reading is 0.16%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.1 and Total Capital is 0.08. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.55.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 76.67 points at the first support level, and at 75.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 77.98, and for the 2nd resistance point, it is at 78.42.
Hologic, Inc. [HOLX] reported earnings per share of $0.98 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.95/share, meaning a difference of $0.03 and a surprise factor of 3.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.89 per share as compared to estimates of $0.84 per share, a difference of $0.05 representing a surprise of 6.00%.
Ratios To Look Out For
For context, Hologic, Inc.’s Current Ratio is 3.89. Further, the Quick Ratio stands at 3.18, while the Cash Ratio is 2.15. Considering the valuation of this stock, the price to sales ratio is 4.58, the price to book ratio is 3.91 and price to earnings (TTM) ratio is 36.86.
Transactions by insiders
Recent insider trading involved GARRETT SCOTT T, Director, that happened on Mar 14 ’24 when 16441.0 shares were sold. Director, CRAWFORD SALLY completed a deal on Mar 08 ’24 to sell 9039.0 shares. Meanwhile, Director Dockendorff Charles J sold 1465.0 shares on Mar 08 ’24.
